EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2015

  • ID: 3429822
  • Report
  • August 2015
  • 129 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AB Science SA
  • Advancell
  • BioNovion B.V.
  • Eisai Co., Ltd.
  • iDD biotech SAS
  • Johnson & Johnson
  • MORE
B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2015

Summary

The report ‘B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2015’, provides an overview of the B-Cell Chronic Lymphocytic Leukemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Chronic Lymphocytic Leukemia and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for B-Cell Chronic Lymphocytic Leukemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the B-Cell Chronic Lymphocytic Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the B-Cell Chronic Lymphocytic Leukemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AB Science SA
  • Advancell
  • BioNovion B.V.
  • Eisai Co., Ltd.
  • iDD biotech SAS
  • Johnson & Johnson
  • MORE
List of Tables

List of Figures

Introduction

REPORT COVERAGE

B-Cell Chronic Lymphocytic Leukemia Overview

Therapeutics Development

Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Overview

Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis

B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Development by Companies

B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Investigation by Universities/Institutes

B-Cell Chronic Lymphocytic Leukemia - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

B-Cell Chronic Lymphocytic Leukemia - Products under Development by Companies

B-Cell Chronic Lymphocytic Leukemia - Products under Investigation by Universities/Institutes

B-Cell Chronic Lymphocytic Leukemia - Companies Involved in Therapeutics Development

AB Science SA

AbbVie Inc.

Advancell

Amgen Inc.

BioNovion B.V.

Celgene Corporation

Dynavax Technologies Corporation

Eisai Co., Ltd.

F. Hoffmann-La Roche Ltd.

Formula Pharmaceuticals, Inc.

iDD biotech SAS

Immunomedics, Inc.

Johnson & Johnson

Juno Therapeutics Inc.

Nippon Shinyaku Co., Ltd.

Noxxon Pharma AG

Ono Pharmaceutical Co., Ltd.

Regeneron Pharmaceuticals, Inc.

SBI Biotech Co., Ltd.

TheraMAB LLC

Vivia Biotech, S.L.

B-Cell Chronic Lymphocytic Leukemia - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

202-b - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AB-8779 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

acadesine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

alemtuzumab biosimilar - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AMG-319 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

bafetinib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BION-1301 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cell Therapy for Hematological Malignancies - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cell Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cell Therapy to Activate CD40L and to Target CD19 for B-Cell Malignancies - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cell Therapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cell Therapy to Target CD16 for CLL and NHL - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cell Therapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cell Therapy to Target CD19 for Cancer - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cell Therapy to Target CD19 for Oncology - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cell Therapy to Target CD23 for B-Cell Chronic Lymphocytic Leukemia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

E-7449 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GNKS-356 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

IDD-001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

IDD-002 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ilorasertib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

JNJ-64052781 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

lenalidomide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MAT-303 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

olaptesed pegol - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ONO-4059 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

REGN-1979 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SD-101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TAB-08 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

tocilizumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Vivia-009 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

B-Cell Chronic Lymphocytic Leukemia - Recent Pipeline Updates

B-Cell Chronic Lymphocytic Leukemia - Dormant Projects

B-Cell Chronic Lymphocytic Leukemia - Discontinued Products

B-Cell Chronic Lymphocytic Leukemia - Product Development Milestones

Featured News & Press Releases

Apr 06, 2015: Juno Therapeutics Announces Patent Litigation Settlement

Dec 12, 2011: CytRx Announces Presentation Of Favorable Phase II Results With Bafetinib In Relapsed B-Cell Chronic Lymphocytic Leukemia At ASH Conference

Nov 15, 2011: TheraMAB launches Phase I clinical trial of first-in-class agonistic monoclonal antibody TAB08 in Russia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2015

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Products under Investigation by Universities/Institutes, H2 2015

B-Cell Chronic Lymphocytic Leukemia - Pipeline by AB Science SA, H2 2015

B-Cell Chronic Lymphocytic Leukemia - Pipeline by AbbVie Inc., H2 2015

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Advancell, H2 2015

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Amgen Inc., H2 2015

B-Cell Chronic Lymphocytic Leukemia - Pipeline by BioNovion B.V., H2 2015

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Celgene Corporation, H2 2015

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Dynavax Technologies Corporation, H2 2015

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Eisai Co., Ltd., H2 2015

B-Cell Chronic Lymphocytic Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Formula Pharmaceuticals, Inc., H2 2015

B-Cell Chronic Lymphocytic Leukemia - Pipeline by iDD biotech SAS, H2 2015

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Immunomedics, Inc., H2 2015

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Johnson & Johnson, H2 2015

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Juno Therapeutics Inc., H2 2015

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Nippon Shinyaku Co., Ltd., H2 2015

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Noxxon Pharma AG, H2 2015

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015

B-Cell Chronic Lymphocytic Leukemia - Pipeline by SBI Biotech Co., Ltd., H2 2015

B-Cell Chronic Lymphocytic Leukemia - Pipeline by TheraMAB LLC, H2 2015

B-Cell Chronic Lymphocytic Leukemia - Pipeline by Vivia Biotech, S.L., H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

B-Cell Chronic Lymphocytic Leukemia Therapeutics - Recent Pipeline Updates, H2 2015

B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, H2 2015

B-Cell Chronic Lymphocytic Leukemia - Dormant Projects (Contd..1), H2 2015

B-Cell Chronic Lymphocytic Leukemia - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2015

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015
Note: Product cover images may vary from those shown
3 of 4
AB Science SA
AbbVie Inc.
Advancell
Amgen Inc.
BioNovion B.V.
Celgene Corporation
Dynavax Technologies Corporation
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd.
Formula Pharmaceuticals, Inc.
iDD biotech SAS
Immunomedics, Inc.
Johnson & Johnson
Juno Therapeutics Inc.
Nippon Shinyaku Co., Ltd.
Noxxon Pharma AG
Ono Pharmaceutical Co., Ltd.
Regeneron Pharmaceuticals, Inc.
SBI Biotech Co., Ltd.
TheraMAB LLC
Vivia Biotech, S.L.
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll